Molecular Epidemiology in Environmental Health: The Potential of Tumor Suppressor Gene p53 as a Biomarker Jan C. Semenzal and Lisa H. Weasel2 'Centers for Disease Control and Prevention, Atlanta, Georgia; 2Emory University, Atlanta, Georgia One of the challenges in environmental health is to attribute a certain health effect to a specific environmental exposure and to establish a cause-effect relationship. Molecular epidemiology offers a new approach to addressing these challenges. Mutations in the tumor suppressor gene p53 can shed light on past environmental exposure, and carcinogenic agents and doses can be distinguished on the basis of mutational spectra and frequency. Mutations in p53 have successfully been used to establish links between dietary aflatoxin exposure and liver cancer, exposure to ultraviolet light and skin cancer, smoking and cancers of the lung and bladder, and vinyl chloride exposure and liver cancer. In lung cancer, carcinogens from tobacco smoke have been shown to form adducts with DNA. The location of these adducts correlates with those positions in the p53 gene that are mutated in lung cancer, confirming a direct etiologic link between exposure and disease. Recent investigations have also explored the use of p53 as a susceptibility marker for cancer. Furthermore, studies in genetic toxicology have taken advantage of animals transgenic for p53 to screen for carcinogens in vivo. In this review, we summarize recent developments in p53 biomarker research and illustrate applications to environmental health. - Environ Health Perspect 105(Suppl 1):155-163 (1997) Key words: aflatoxin B1, biomarker, cancer, environmental health, exposure, genetic toxicol- ogy, mutations, p53, polymorphism, risk assessment, smoking, susceptibility, ultraviolet light, vinyl chloride Introduction Because environmental exposures to chemi- cal agents or radiation can occur at low Ilevels over long periods of time, it is often difficult to determine associations between exposure and disease, let alone prove causal- ity. Therefore, investigations concerning the health consequences of environmental exposure face a multitude of challenges. First, the environmental fate of xenobiotic agents must be evaluated before they come into contact with human populations. Factors such as transformation, bioaccumu- lation, and bioavailability in the environ- ment will differentially affect the exposure an individual receives (1) and the routes by which an individual is exposed. In addition, population heterogeneity and interactions between biological variables such as inherited metabolic characteristics and synergistic effects of multiple envirorunental exposures may play an important role as well. Once the complex task of establishing exposure levels has been addressed, health risks resulting from such exposure can be determined. Toxicological dose-response relationships and threshold effects are usually extrapolated from animal data. Molecular epidemiology offers a new approach to establish associations between exposure and disease by using types and frequencies of mutations as molecular dosimeters (2-4). Manuscript received 29 May 1996; manuscript accepted 23 September 1996. The authors thank M.T. Smith for his invaluable support of this review. We would also like to acknowledge L. Balluz, H. Falk, D. Flanders, A. Henderson, M. Khoury, M. McGeehin, C. Rubin, T. Sinks, and A. Wasley for their helpful comments on the manuscript. Address correspondence to Dr. J.C. Semenza, Centers for Disease Control and Prevention, National Center for Environmental Health, F-46, 4770 Buford Highway NE, Atlanta, GA 30341-3724. Telephone: (770) 488-7649. Fax: (770) 488-7335. E-mail: yzs4@cehdehl .em.cdc.gov Abbreviations used: AFB1, aflatoxin B1; Arg, arginine; ASL, angiosarcoma of the liver; BlalP, benzo[alpyrene; BCC, basal cell carcinoma; CDK, cyclin dependent kinase; DMN, dimethylnitrosamine; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; PAH, polycyclic aromatic hydrocarbon; Pro, proline; SCC, squamous cell carci- noma; TSG, tumor suppressor gene; UV, ultraviolet. By combining environmental epidemi- ology with modern molecular techniques, molecular epidemiology attempts to find answers to questions regarding exposure and risk (5). For example, is the lung cancer of a miner due to environmental radon expo- sure or smoking? Do dietary carcinogens play a role in the liver cancer of a patient, or is the disease a result of endogenous processes? Molecular epidemiology offers a new approach to risk assessment in cases such as these. The first interaction between xenobiotic compounds and organisms occurs on a molecular level prior to any clinical mani- festation. Thus, if a target molecule of a toxic agent is known, changes in that mole- cule may be used as a biomarker and the biological dose or effect of an environmen- tal exposure may be measured directly in biological samples. The power of molecular epidemiology in environmental exposure assessment lies in the use of such biomark- ers, which attempt to infer exposure and identify exposure-related health risks. When biomarkers are used to directly measure the molecular impact of exposure, subclinical responses can be detected. Therefore, biomarkers allow exposure to be determined prior to any dinical manifesta- tion of health effects, allowing the mini- mization of adverse outcomes through the prevention of continued exposure. The tumor suppressor gene (TSG) p53 is an ideal biomarker of effect for addressing such questions of exposure and risk. The p53 gene is expressed in every cell of the human body and the p53 protein has been shown to play a crucial role in the regulation of cell division, making it a central molecule in the life of a cell (6). Inactivation of the p53 gene can result in uncontrolled cell division and ultimately lead to cancer (7). Such inactivation frequently occurs as a result of mutations caused by exposure to environmental mutagens (3,4). However, inactivation of p53 can also occur sporadi- cally through endogenous processes, and in rare cases, mutations in p53 can be inher- ited. The ability to distinguish between dif- ferent types of mutations in p53 as well as to link exposure to specific patterns and types of mutations in the gene makes p53 an ideal tool in molecular epidemiology. p53 and Cancer Cancer is a complex process, a result of the cell cycle gone awry. Tight control over cellular proliferation is essential for the life Environmental Health Perspectives * Vol 105, Supplement I * February 1997 -- ----- 155 SEMENZA AND WEASEL of an organism, in which growth is stimu- lated by protooncogenes and counterbal- anced by growth-inhibiting TSGs such as p53. Mutations that activate protooncogenes can turn them into oncogenes and result in tumor growth. On the other hand, muta- tions that inactivate TSGs release growth inhibition, also leading to tumorigenesis (8). While mutations in protooncogenes result in a gain of function and are therefore dominant, overriding the presence of the wild-type copy of the gene, recessive TSG mutations result in loss of function and a single mutant copy will thus be masked by the presence of the remaining wild-type copy (8). Therefore, in most cases, both copies of a TSG must be mutated in order to see an effect. In many instances, one copy of p53 is inactivated by a point muta- tion while the other allele has been deleted (7). The initiation of cancer often results when mutations in both protooncogenes and TSGs occur simultaneously. The p53 gene is one of the most promi- nent members of the TSG family. Its pro- tein product is a nuclear transcription factor (7) that regulates the activity of sev- eral genes, induding that of p2l, which is directly involved in cell cycle control (9-11). p21 exerts its effect by binding to and inactivating cyclin-dependent kinases (CDK), preventing the cell cycle from pro- gressing (Figure 1). Mutated p53 as found in human cancers is unable to activate the p21 gene, leading to a release of the normal cell cycle block and thus to uncontrolled cellular growth (12). Control of the cell cycle checkpoint becomes increasingly important when a cell has suffered from extensive DNA damage. p53 plays a crucial role in preventing such cells from multiplying by initiating pro- grammed cell death (apoptosis) (13-15). When p53 is mutated and can no longer activate apoptosis, such damaged cells are able to continue proliferating, potentially resulting in cancer. p53 as a Biomarker The usefulness of p53 as a biomarker of effect is 5-fold: a) p53 is altered in tumors of more than 50% of all cancer patients (16-18). This finding reflects the central role played by p53 in cell cycle control and cancer. This high prevalence of p53 mutations means that the probability of finding mutations in this gene in a given cancer patient popula- tion is likely, allowing for the establish- ment of statistically significant associations between mutations and exposures. p53 p21~~~~~~~~2 l pi | l Growth inhibition Normal cell division Environmental or Endogenous agent mechanisms 5 3p53 A2 p21 ?ncDK Figure 1. Transcriptional activation of the p21 gene by p53 and cyclin-mediated cell cycle control. b) Mutations in the p53 gene are found in nearly all types of cancer studied (19). Because mutations in p53 are widespread, having been identified in such diverse types of cancer as lung, breast, colon, esophagus, lymphomas, and leukemias, (16) p53 is a useful tool for assessing associations between environmental exposure and a multiplicity of types of cancer. Thus, p53 lends itself to the study of the carcinogenic process in relation to carcinogens even in the case of rare tumor types. c) Specific types of cancer are associated with characteristic mutation patterns in p53. Particular mutation patterns in p53 have been observed to correlate with specific types of cancer (16). The so-called mutational spectrum, the pattern of loca- tion and type of mutations within the p53 gene, has been shown to differ between cancers of the lung, colon, liver, breast, brain, esophagus, reticuloendothelial tissue, and hemopoetic tissues, allowing investiga- tion of the etiology of the carcinogenic process in different tissues. d) Specific mutational spectra in p53 can be linked to specific exposures (18). Most importantly for environmental health, certain mutagens have been shown to leave mutational fingerprints in the p53 gene-characteristic patterns of mutations that can be indicators of specific exposures. On the basis of these fingerprints, endoge- nous mutagenic events can often be distin- guished from those resulting from exposure to exogenous agents, thus shedding light on the etiology and molecular pathogenesis of cancer. Furthermore, it has been possible to identify carcinogens on the basis of such mutational spectra and to determine the dose by using the frequency of mutations as a molecular dosimeter (3,18). e) The location of adducts between car- cinogens and DNA can be mapped along the sequence of p53 (20). Preferential loca- tion of such adducts at particular positions in the p53 gene correlates with the sites of mutational hot spots found in certain cancer types. Thus, the p53 gene can be used to identify direct causal links between chemical exposures and disease. p53 and Exposure Assessment Because of the widespread involvement of p53 in many types of cancer, significant information concerning links between specific exposures, mutations in p53, and cancer type is available. The p53 gene has been isolated and sequenced in a wide vari- ety of cancers and the presence of signature mutations in several exposure-induced types of cancer has been described (Table 1). These findings indicate that the p53 gene can be used as an indicator to reconstruct exposure and to identify the carcinogen responsible for the mutation. Mutations resulting from endogenous mechanisms are thought to differ from exposure-induced events. For example, more than two-thirds of the mutations found in colon cancer are transitions at CpG sites (16). It has been Environmental Health Perspectives * Vol 105, Supplement l * February 1997 Growth stimulation Cancer 156 THE USE OF p53 AS A BIOMARKER Table 1. Exposure to environmental agents, mutation in p53, and cancer outcome. Exposure Cancer type Mutation in p53 Reference Dietary aflatoxin Hepatocellular carcinoma G-T or G-+C transversions, (21-23) (liver) particularly at codon 249 UV irradiation Squamous and basal cell C->T substitutions at dipyrimidine sites (24-26) carcinomas (skin) Tobacco smoke Lung cancer G:C to T:A transversions, (16,27-30) particularly at codons 157, 248, 273 Bladder cancer G:C to C:G transversions, higher double (31,32) mutation frequency Vinyl chloride Angiosarcoma (liver) A:T to T:A transversions, anti-p53 (33,34) antibodies in sera speculated that CpG sites are susceptible to spontaneous methylation followed by deamination and that the resulting muta- tion is due to endogenous rather than exogenous processes (3). The usefulness of p53 in exposure assessment is illustrated in the following sections. Dietary Aflatoxin B1 One of the best documented examples of the value of p53 as a biomarker of effect is the association that has been established between exposure to dietary aflatoxin B1 (AFB1), hepatocellular carcinoma (HCC) of the liver, and mutation in the p53 gene. AFB1, a fungal mycotoxin produced by Aspergillus flavus, is a common contami- nant in grains, nuts, and oil seeds in cer- tain geographical regions. In areas where exposure is endemic, such as sub-Saharan Africa and southern China, dietary AFB1 is considered a major risk factor for HCC (35,36), which occurs at high levels in the population. Hepatitis B infection is often also common in these regions and is considered to have a substantial and perhaps synergistic causative role in the development of HCC (37,38). Examination of the p53 gene in HCC tumors from patients residing in Qidong, China, an area of both high AFB1 exposure and endemic Hepatitis B infection, revealed a prevalence of point mutations at the third base position of codon 249. Many of the point mutations observed were G-*T or G-*C transversion events (21). In contrast, nonmalignant liver tissue from patients with p53 mutations in the tumor showed no mutation in p53. Thus, there is a striking correlation between the presence of p53 mutation and malignancy. Studies of HCC tumors from patients resid- ing in sub-Saharan Africa, also a region of both high AFB1 exposure and high rates of hepatitis B virus (HBV) infection, revealed strikingly similar patterns of mutation in the p53 gene; many of the mutations observed were G-+T transversions, with a hot spot at codon 249 (22). An association between dietary AFB1 exposure and G->T transversions in HCC is supported by in vitro studies that have demonstrated that metabolites of AFB1 are capable of binding to DNA and inducing G-+T transversions (23). In studies of DNA-repair deficient human cells, AFB1 metabolite exposure resulted in a high fre- quency of base substitutions at G:C pairs and transition mutations at GG sites. Furthermore, experiments in which human hepatocytes were exposed to AFB1 metabo- lites in vitro revealed a high frequency of G->T transversion events at codon 249, a result consistent with observations in tumors from populations in areas with high AFB1 exposure (39). Whereas these studies implicate AFBi exposure in specific patterns of mutation in p53, HBV infection has also been estab- lished as a risk factor for HCC and there- fore is likely to also play a role in events leading to carcinogenesis. However, a study of HCC in Hong Kong, a high prevalence area for HBV infection but a low-exposure area for AFB1, showed a lower frequency of mutation in p53 than was observed in tumors from China and sub-Saharan Africa, with no clustering of mutations at codon 249 (40). In addition, when tumors from Qidong, China, were assessed for the presence of HBV infection, no correlation was found between the state of HBV DNA and mutations in p53 (41). Experimental evidence suggests that HBV infection is likely to contribute to HCC by inhibiting the activity of wild-type p53, rather than through mutagenesis of the p53 gene. A protein encoded by HBV, pro- tein X, has been shown to bind to the wild- type p53 gene product and inhibit its DNA binding and transcriptional activity in vitro (42). Thus, it is likely that HBV infection increases the probability of developing HCC as a result of a synergistic effect with mutations in p53 stemming from AFB1 exposure. The specificity of the link between G-4T transversion events, particularly at codon 249, and AFB1 exposure is further supported by studies of HCC cases from regions where neither AFBI exposure nor HBV infection is common. One of these studies revealed a high frequency of p53 overexpression in HCC tumor cells linked to mutations in the p53 gene (43). However, the codon 249 mutation that was frequently observed in AFBI-exposed populations was not a predominant muta- tion event in these HCCs (43). Studies with additional cases showed no consistent pattern of mutation in p53 and the fre- quency of mutation at codon 249 was low (44,45). Additional support for the causal- ity of AFB1 in the development of HCC is provided by the presence of mutations at codon 249 in nonmalignant liver tissue from HCC patients in areas with high AFB1 exposure (46). These studies corrob- orate the evidence linking exposure to AFB1 with mutations at codon 249 of the p53 gene in cases of HCC tumors. Ultraviolet Irradiation Exposure to ultraviolet (UV) irradiation has been implicated in the etiology of many types of skin cancers (47). Because UV exposure is often preventable by the use of sunscreens or the reduction of time spent in the sun, public health implications of the relationship between UV exposure and skin cancer are of great practical impor- tance. Because UV exposure is well estab- lished as the most consistent and significant cause of skin cancer in humans, the ability to locate specific patterns of mutation in p53 on the causal pathway between expo- sure and disease provides an excellent example of the power of biomarkers in assessing environmental exposure. Exposure to UV light has been shown to increase the risk of squamous cell (SCC) and basal cell (BCC) carcinomas, as well as the risk of melanoma (47,48). At the mol- ecular level, it has been demonstrated that exposure to UV light leads to CC-4TT double base substitutions and C-?T substitutions at dipyrimidine sites. Such dipyrimidine mutations are a signature of UV exposure; rarely do these types of mutations result from exposure to other mutagens (49,50). In cases of skin cancer, particularly SCC (24) and BCC (25,26), mutations in p53 have been detected predominantly at Environmental Health Perspectives * Vol 105, Supplement 1 * February 1997 157 SEMENZA AND WEASEL dipyrimidine sites and are frequently C-4T substitutions, suggesting a relationship between UV exposure, p53, and carcino- genesis. Further implicating an association between UV exposure and the presence of p53 mutations in these cases is the fact that all of the tumors in which p53 mutations were observed came from sun-exposed sites on the body, whereas tumors occurring at nonexposed sites on the body showed no correlation with mutations in p53 (25,51). When normal skin cells were subjected to varying degrees of UV irradiation in vitro and assessed for CC->TT transitions at codons 245 and 247/248 of p53, such mutations were observed to occur accord- ing to a dose-response relationship. The presence of pyrimidine dimer mutations at certain hot spots in the p53 gene is thought to be a result of slow repair of dimers at specific sites (52). Smoking Tobacco smoking has been associated with an elevated risk for multiple types of human cancers (53,54). Moreover, several of the approximately 3800 chemicals identified in tobacco smoke have been shown to cause cancer in laboratory ani- mals (55). Two components of tobacco smoke, benzo[a]pyrene (B[a]P), a poly- cyclic aromatic hydrocarbon (PAH), and 4-aminobiphenyl, an arylamine, form adducts with DNA, suggesting that these components may be direct mutagens. DNA adducts containing B[a]P have been found in lung tumors from smokers (56-59) and 4-aminobiphenyl has been identified in DNA adducts in bladder tumors from smokers (60). The presence of tobacco smoke components in DNA adducts from smoking-associated tumors strongly suggests that direct DNA mutage- nesis plays a role in the increased cancer risk associated with tobacco smoking. Several studies have determined that G:C to T:A transversions are the most commonly observed mutation events fol- lowing experimental exposure to polycyclic aromatic hydrocarbons such as B[a]P (27-30,61), and other components of tobacco smoke have been shown to lead to G:C to T A transversions as well (16,62). Studies investigating p53 mutations in lung cancers have shown that G:C to T:A transversions on the nontranscribed strand of the p53 gene occur at a significantly higher frequency in lung cancers than in other types of cancer (4,63,64), suggesting an association between exposure to tobacco smoke components, such as PAHs, and these mutations. Conversely, the frequency of transition mutations at CpG residues, presumed to arise from endogenous causes, is also significantly lower overall in lung cancer than in most other types of cancer. This would suggest a stronger than usual role of direct mutagenesis in lung cancers as compared to other types of cancer. However, among the small subgroup of lung cancers occurring in nonsmokers (tobacco smoking is thought to account for up to 90% of all pulmonary malignancies), the pattern is reversed. Fewer incidences of G:C to T:A transversion events in p53 have been observed; most of the p53 mutations in these cancers are G:C to A:T transition mutations (65,66). Thus, the specific and distinctive mutation pattern of G:C to T:A transversion events in the p53 gene pre- dominates in cases of lung cancer associ- ated with smoking, whereas lung cancer cases not associated with smoking tend to display the more widespread and endoge- nous G:C to A:T transition mutations. Therefore, the presence of G:C to T:A transversions in the p53 gene, particularly on the nontranscribed strand, serves as a specific biomarker of effect of tobacco smoke and is likely to be induced by one or more components found in tobacco smoke. Further supporting the association between such mutations in p53, lung cancer, and smoking are the results of sev- eral studies (64-66). These studies show that in lung cancers not only is there a direct association between smoking and the frequency of mutation or state of the p53 protein, but the relative frequency of such events correlates with lifetime cigarette con- sumption. Additionally, several hot spots at guanine residues have been identified in lung cancers at codons 157, 248, and 273, which lie within the DNA binding domain of p53 (20). Of these, the mutational hot spot at codon 157 is specific for lung cancer and has not been identified as a hot spot in other cancer types. Recently, a direct etiologic link between tobacco smoke and lung cancer has been established in a study examining B[a]P adduct formation in the p53 gene (Figure 2). When bronchial epithelial cells were exposed to benzo[a]pyrene diol epoxide, the metabolically active form of B[a]P, strong and selective adduct formation was observed at codons 157, 248, and 273 (20). Since these codons are identical to those mutated in lung cancer, this finding for- mally establishes the link between exposure and disease in tobacco smoke exposure. Tobacco smoking has also been associ- ated with increased risk for bladder cancer (67-72). Mutations in p53 were one of the first genetic alterations to be associated Normal cell p p53 DNA adduct formation Exposure: tobacco smoke ; Cancer cells Disease: lung cancer Figure 2. Causal link between exposure and disease: tobacco smoke and lung cancer. Environmental Health Perspectives - Vol 105, Supplement I * February 1997 158 THE USE OF p53 AS A BIOMARKER with primary invasive bladder cancers (73). In immunohistocytochemical studies of patients with early stage bladder cancer, a significant association between the number of cigarettes smoked per day and the fre- quency of nuclear staining for p53 was observed (74). Studies comparing cases of bladder cancer from smoking and non- smoking patients showed that an increased frequency of G:C to C:G transversion events in the p53 gene was associated with both groups (31,32). Although no differ- ence in the spectrum of mutation types was found, smokers were observed to have a higher frequency of double mutation events in the p53 gene. One study of Japanese patients with a variety of urothelial cancers, including bladder cancer, showed that although the frequency of p53 mutation did not substantially differ between smok- ers and nonsmokers, tumors from smokers exhibited A:T to G:C transitions in the p53 gene at a significantly higher frequency than tumors from nonsmokers (31). Vinyl Chloride Occupational exposure to vinyl chloride during the manufacture of plastics has been tied to the occurrence of angiosarcoma of the liver (ASL), a rare form of cancer (75,76). Most exposure to vinyl chloride occurred between 1950 and 1980, prior to the discovery of its carcinogenic effect. Because such exposure has been remark- ably well documented, studies of workers exposed to vinyl chloride provide an excel- lent opportunity for establishing associa- tions between environmental exposure, mutation spectra, and ASL. Serum from workers exposed to vinyl chloride tested positive for anti-p53 anti- bodies; many of those who tested positive either had ASL at the time of testing or went on to develop ASL at a later date (33). In contrast, serum from lung cancer patients tested positive at a significantly lower frequency, whereas serum taken from individuals with neither vinyl chloride exposure nor cancer showed no reactivity at all (33). Thus, the presence of anti-p53 antibodies in serum from workers exposed to vinyl chloride may be a useful indicator for risk or presence of ASL. When ASL tumors from workers exposed to vinyl chloride were analyzed for mutations in p53, a significant frequency of A:T to T:A transversions, an uncommon mutation event in the majority of human types of cancer, was observed (34). Tumor tissues from those vinyl chloride-exposed workers who tested positive for anti-p53 antibodies also showed these unusual A:T to T:A transition events in p53 (33). Usually, mutations in p53 are rare events in sporadic ASL (77) and when they do occur, they are usually G:C to A:T transi- tions consistent with endogenous mecha- nisms. However, A:T to T:A transversions are characteristic of chloroethylene oxide, a carcinogenic metabolite of vinyl chlorides (76). Therefore, such mutations can be used as biomarkers of effect resulting from exposure to vinyl chloride. p53 as a Susceptibility Marker Mutations p53 mutations can be inherited as well as acquired. Individuals with the rare Li- Fraumeni syndrome are at increased risk of acquiring breast carcinomas, soft tissue sar- comas, brain tumors, osteosarcomas, leukemia, and adrenocortical carcinomas (78). This syndrome results from germline mutations in p53 (79). Although individuals carrying germline mutations in p53 can usually be identified on the basis of a family history of cancer (i.e., Li-Fraumeni syndrome), the identi- fication of individuals at risk who lack such a family history poses technical problems for traditional techniques. In the absence of a family history of cancer, a molecular assay developed in yeast can be used to screen for individuals with germline muta- tions (80). This functional assay distin- guishes between mutations that affect the function of the protein (and are therefore likely to lead to increased susceptibility to cancer) and polymorphisms not likely to alter wild-type p53 function. Polorphisms Polymorphisms differ from mutations in that they occur at a higher frequency in the population (> 1%) and do not necessarily affect the function of the protein. In many cases, polymorphisms do not alter the amino acid sequence, although they some- times alter the expression of the gene. Therefore, polymorphisms in p53 cannot be identified by the functional yeast assay because they do not affect protein function (although they can still result in a predispo- sition for certain cancers). To date, several polymorphisms in p53 have been described, two of which have been implicated in cancer susceptibility and are described below. Codon 72 (Pro) Polymorphism The wild-type form of the p53 protein occurs in two variants at codon 72, arginine (Arg) and proline (Pro), which appear to be functionally equivalent. An initial study investigating smoking-associated lung cancer in Japan identified a possible associ- ation between the homozygous Pro/Pro polymorphism at codon 72 of the p53 gene and cancer risk (81). Additional studies found a similarly increased fre- quency of the Pro/Pro polymorphism at codon 72 in smoking-related cancers, although the statistical significance of these results was borderline (82,83). The impor- tance of polymorphisms in codon 72 as a marker for cancer susceptibility remains to be determined. Polymorphism in Intron 3 A recent study with a Swedish population of lung cancer patients determined that the Pro/Pro polymorphism at codon 72 itself showed no association with cancer; in com- bination with the lack of a 16 bp duplica- tion in intron 3 of the p53 gene, however, the Pro/Pro polymorphism was associated with risk for lung cancer (84). The same disequilibrium between the Pro/Pro poly- morphism at codon 72 and the lack of the 16 bp duplication has been associated with increased risk for colorectal cancer (85). Conversely, the presence of the same 16 bp duplication in intron 3 has recently been associated with sporadic ovarian cancer in a population of Caucasian Germans (86). However, an increased allele frequency for the 16 bp insertion was not detected in an American population of ovarian cancer patients, possibly as a result of geographic differences and allele frequencies (87). Because there is no consistent causal rela- tionship between either the absence or the presence of the 16 bp insertion in intron 3 and cancer, both this polymorphism and the Pro/Pro polymorphism at codon 72 in the p53 gene are probably linkage markers for an as-yet unidentified region that confers susceptibility to cancer (84). The use of susceptibility markers to identify individuals with an inherited pre- disposition to cancer can improve the efficiency of cancer screening and cancer prevention efforts. A simple blood test has been used to identify the 16 bp insertion polymorphism in patient serum and could be applied to circumvent the traditionally difficult diagnosis of early ovarian cancer by identifying individuals at risk. If cancer- prone individuals can be identified by the use of susceptibility markers, they can be assisted in minimizing environmental exposures (i.e., tobacco smoke) that put them at increased risk. Environmental Health Perspectives * Vol 105, Supplement 1 * February 1997 159 SEMENZA AND WEASEL p53 in Genetic Toxicology Cancerogenesis is thought to be a multistage process involving initiation, promotion, and progression. Understanding how carcinogens function requires the elucida- tion of the roles they play in each of these stages of cancer development. Because p53 is a central molecule in cell cycle regulation and growth control, its interaction with various carcinogens can shed light on the ways in which they contribute to the cancerous state. The development of transgenic animals possessing null alleles of p53 provides an in vivo model for analysis of carcinogen func- tion. Although animals homozygous for null alleles of p53 have been shown to be developmentally normal, they have shown an increased susceptibility to spontaneous tumors, thus making them inappropriate for toxicological studies (88). However, animals heterozygous for null alleles of p53 have a reduced rate of spontaneous tumors relative to homozygotes; these animals have proven to be useful tools for studying the carcinogenic process and for identifying carcinogens and teratogens. Transgenic mice possessing one copy of a null allele of p53 have proven to be valu- able for rapid and sensitive assessment of the effects of xenobiotic exposures in rela- tion to the timing of tumorigenesis. A recent study of skin cancer in such animals found that in one instance of chemically induced tumorigenesis, p53 was involved in malignant progression but not in initiation or promotion (89). Heterozygous null p53 animals can also be useful in identifying chemicals that are potential environmental carcinogens. Exposure of these animals to dimethyl- nitrosamine (DMN), a potent liver car- cinogen, showed a higher frequency of spontaneous tumors than in exposed wild- type animals, providing a sensitive assay with which to assess the effects of carcino- gens (90). Furthermore, in heterozygous null animals, the mutational spectra for specific chemicals can be evaluated for dif- ferent types of cancer and compared with human data. Certain mutant forms of p53 can be reintroduced into heterozygous null and homozygous null mice in order to study the selective predisposition of cer- tain mutant forms of p53 to specific tumor type (91,92). Such mice can also aid in the determination of signature muta- tions in p53 in cases of radiation-induced tumors, since p53-deficient mice are highly susceptible to even minor doses of radiation (93,94). Transgenic mice deficient for p53 have also been used to screen for environmental teratogens and have been found to be a sensitive tool with which to study embry- onic development. In one such study, the embryotoxicity and teratogenicity of benzo[a]pyrene was found to be 2- to 4-fold higher in p53-deficient mice than in wild-type controls (95). In utero death was 2.6- and 3.6-fold higher, respectively, in heterozygous and homozygous p53- deficient embryos. However, neither standardized lifetime bioassays in wild-type rodents exposed to daily, near-toxic doses, nor short-term tests to assess the mutagenicity of chemicals in wild-type animals, have resulted in p53 mutational spectra comparable to that seen in human cancers. Thus, p53 seems not to play the same central role in animal tumorigenesis as it does in human tumori- genesis (96). These newly developed p53- deficient mice will aid genetic toxicology in identifing natural and synthetic com- pounds that pose potential risk to human health (97). In controlled animal experi- ments, the effect of a certain chemical on p53 can be evaluated and compared with results from exposed human populations. Methods for Identifying Mutations in p53 Because specific types or patterns of mutation in the p53 gene can serve as indi- cators or predictors of cancers resulting from exposure, the detection of such muta- tions is important not only for establishing a cause-effect relationship between expo- sure and disease, but also for screening of exposed populations prior to the onset of cancer. Therefore, accurate, timely, and cost-efficient methods of identifying such mutations are needed. Three general diag- nostic approaches to the detection of p53 mutations can currently be used to screen for mutations in p53. The first and most direct approach is to evaluate the p53 gene sequence from tumor tissue and analyze it for mutations. How- ever, since this is often a time-consuming and cosdy procedure, especially when con- ducted on a widespread basis, other prelim- inary screening approaches are often used to detect cases in which p53 mutation is likely. The most common of these is immunohistochemistry, a method that relies on the increased half-life of many mutant p53 proteins. Because of their longer half- life, mutant p53 proteins can be detected in cells, whereas wild-type p53 eludes detection because of its short half-life (98). Recent studies also indicate that antibodies to p53 are present in the serum of individ- uals with p53 mutations. This can be applied as a screening method; studies of both breast and lung cancer have shown elevated levels of anti-p53 antibodies in the serum of individuals with mutations in p53 (99,100). Analysis of the p53 protein is not always a good indicator of mutations in the p53 gene, since the protein can be inactivated, for example by interactions with viral pro- teins. Furthermore, analysis of the protein by immunohistochemistry cannot deter- mine the type and location of mutations in p53, which is essential information when the p53 gene is used as a biomarker of exposure or dose. Therefore, even when analysis of the p53 protein suggests that a mutation may be present, it is still necessary to screen for mutations at the gene level. There are several ways that the p53 gene can be analyzed at the genetic level and screened for mutations in its sequence. If the site of the mutation is not known, prescreening with denaturing gradient gel electrophoresis or single-strand conforma- tion polymorphism can be used (101,102). Either of these two methods will allow rapid screening of mutations without labor-intensive sequencing of the entire gene. When the location of the mutation has been narrowed to a particular exon, polymerase chain reaction in combination with restriction fragment length polymor- phism can effectively identify the specific nature of individual mutations (103,104). If no restriction site is associated with the mutation in question, then direct sequenc- ing must be used to determine the nature of the mutation. Limitations Population-based studies are needed to evaluate critical epidemiologic features of p53, such as the predictive value positive, sensitivity, and specificity. Studies pre- sented in this review are predominantly case reports and thus the prevalence of p53 mutations in the general population cannot be estimated. Therefore, it is difficult to estimate how predictive a cer- tain mutation is for a specific exposure with the data available in the current liter- ature. It would be desirable to use p53 as a biomarker of effect in different epidemio- logic study designs such as cohort and case control. Rigorous epidemiologic evalua- tion of such data would be required to translate and implement these findings in public health practice. Environmental Health Perspectives * Vol 105, Supplement I* February 1997 160 THE USE OF p53 AS A BIOMARKER Furthermore, there are substantial ethical considerations which must be taken into account concerning the use of p53 as a biomarker in public health. The use of such biomarkers is susceptible to consider- able abuse, i.e. cancellation of insurance policies and violation of equal opportunity laws. Therefore, the practical implication of p53 as a biomarker may be limited due to social restraints. Conclusions In this brief review we have restricted our discussion to p53 research as it pertains to environmental health. Because of the primary role p53 plays in the life of a cell, induding its involvement in apoptosis, DNA repair, and cell proliferation and division, a vast body of knowledge exists regarding its func- tion (6). This knowledge can be applied to the development of effective environmental health tools for using p53 as a biomarker of effect. Several examples of mutational spec- tra associated with specific exposures and doses have already been elucidated; further research is likely to extend the range of envi- ronmental exposures that can be associated with disease through the use of p53. In particular, p53 shows promise for the assessment of cancer susceptibility as well as for in vivo identification of carcinogens. More work is needed to identify specific markers for susceptibility, and the develop- ment of animals transgenic for p53 is likely to facilitate an understanding of how car- cinogens act on p53 and lead to cancer. The use of biomarkers, particularly genes such as p53, is a rapidly expanding field in environmental health and has vast potential for increasing our knowledge and aware- ness of the impact of the environment on human health. REFERENCES 1. Spear RC. Assessing health risks in the presence of variable exposure and uncertain biological effects. In: The Economics and Management of Water and Drainage in Agriculture (Dinar A, Silberman D, eds). Norwell, MA:Kluwer Academic Publishers, 1991. 2. Wogan GN. Molecular epidemiology in cancer risk assessment and prevention: recent progress and avenues for future research. Environ Health Perspect 98:167-178 (1992). 3. Jones PA, Buckley JD, Henderson BE, Ross RK, Pike MC. From gene to carcinogen: a rapidly evolving field in molecular epidemiology. Cancer Res 51:3617-3620 (1991) 4. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 329:1318-1327 (1993). 5. Hulka BS. Biological markers in epidemiological research. Arch Environ Health 42:83-89 (1988). 6. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 266:1821-28 (1994). 7. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 70:523-526 (1992). 8. Weinberg RA. Tumor suppressor genes. Science 254:1138-1146 (1991). 9. El-Deiry WS, Tokino T, Veculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825 (1993). 10. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SL. The p21 Cdk-interacting protein Cipl is a potent inhibitor of GI cyclin-dependent kinases. Cell 75:805-816 (1993). 11. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704 (1993). 12. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumori- genic mutations. Science 265:346-355 (1994). 13. Hale AJ, Smith CA, Sutherland LC, Stoneman VE, Longthorne VL, Culhane AC, Williams GT. Apoptosis: molecular regula- tion of cell death. EurJ Biochem 236(1):1-26 (1996). 14. Elledge RM, Lee WH. Life and death by p53. Bioessays 17(11):923-930 (1995). 15. Evan GI, Brown L, Whyte M, Harrington E. Apoptosis and the cell cycle. Curr Opin Cell Biol 7(6):825-834 (1995). 16. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 muta- tions in human cancers. Science 253:49-53 (1991). 17. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 351:453-456 (1991). 18. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262:1980-1981 (1993). 19. Oliner JD. Discerning the function of p53 by examining its molecular interactions. Bioessays 15(11):703-707 (1993). 20. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential for- mation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274:430-432 (1996). 21. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427-431 (1991). 22. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from south- ern Africa. Nature 350:429-431 (1991). 23. Foster PL, Eisenstadt E, Miller JH. Base substitution mutations induced by metabolically activated aflatoxin B1. Proc Natl Acad Sci USA 80:2695-2698 (1983). 24. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88:10124-10128 (1991). 25. Moles JP, Moyret C, Guillot B, Jeanteur P, Guilhou JJ, Theillet C, Basset-Seguin N. p53 gene mutations in human epithelial skin cancers. Oncogene 8:583-588 (1993). 26. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, Halperin AJ, Baden HP, Shapiro PE, Bale AE, Brash DE. Mutation hot spots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 90:4216-4220 (1993). 27. Mazur M, Glickman BW. Sequence specificity of mutations induced by benzo[a]pyrene-7,8-diol-9,10-epoxide at endoge- nous hprt gene in CHO cells. Somat Cell Mol Genet 14:393-400 (1988). 28. You M, Candrian U, Maronpot RR, Stoner GD, Anderson MW. Activation of the Ki-ras protooncogene in the sponta- neously occurring and chemical y induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA 86:3070 (1989). 29. Chen RH, Maher VM, McCormick JJ. Effect of excision repair by diploid human fibroblasts on the kinds and locations of mutations induced by (+/-) -7 beta, 8 alpha-dihydroxy-9 alpha, 10 alpha-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene in the coding region of the HPRT gene. Proc Natl Aca Sci USA 87:8680 (1990). 30. Ruggeri B, DiRado M, Zhang SY, Bauer B, Goodrow T, Kelin- Szanto AJP. Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc NatI Acad Sci USA 90:1013-1017 (1993). 31. Habuchi T, Takahashi T, Yamada H, Ogawa 0, Kakehi Y, Ogura K, Hamazaki S, Toguchida J, Ishizaki K, Fujita J. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res 53:3795-3799 (1993). 32. Spruck CH, Rideout WM, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, Nichols PW, Horn T, Hermann GG, Steven K. Environmental Health Perspectives * Vol 105, Supplement I * February 1997 161 SEMENZA AND WEASEL Distinct pattern of p53 mutations in bladder cancer: relation- ship to tobacco usage. Cancer Res 53:1162-1166 (1993). 33. Trivers GE, Cawley HL, DeBenedetti VM, Hollstein M, Marion MJ, Bennett WP, Hoover ML, Prives CC, Tamburro CC, Harris CC. Anti-p53 antibodies in sera of workers occupa- tionally exposed to vinyl chloride. J Natl Cancer Inst 87:1400-1407 (1995). 34. Hollstein M, Marion MJ, Lehman T, Welsh J, Harris CC, Martel-Planche G, Kusters I, Montesano R. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed fac- tory workers. Carcinogenesis 15:1-3 (1994). 35. IARC. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Vol 1-42. Suppl 7. Lyon:International Agency for Research on Cancer, 1987;83-87. 36. Wogan GN. Aflatoxins as risk factors for hepatocellular carci- noma in humans. Cancer Res 52:2114s-2118s (1992). 37. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet 2:1129-1133 (1981). 38. Parkin DM, Laara E, Muir CS. Estimates of the worldwide fre- quency of sixteen major cancers in 1980. Int J Cancer 41:184-197 (1988). 39. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G->T in codon 249 of the p53 tumor suppres- sor gene in human hepatocytes. Proc Natl Acad Sci USA 90:8586-8590 (1993). 40. Ng IO, Chung LP, Tsang SW, Lam CL, Lai EC, Fan ST, Ng M. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene 9(3):985-990 (1994). 41. Li D, Cao Y, He L, Wang NJ, Gu JR. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis 14(2):169-173 (1993). 42. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu J, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 91:2230-2234 (1994). 43. Volkmann M, Hofmann WJ, Muller M, Rath U, Otto G, Zentgraf H, Galle PR. p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 9:195-204 (1994). 44. Debuire B, Paterlini P, Pontisso P, Basso G, May E. Analysis of the p53 gene in European hepatocellular carcinomas and hepa- toblastomas. Oncogene 8:2303-2306 (1993). 45. Hsieh DP, Atkinson DN. Recent aflatoxin exposure and muta- tion at codon 249 of the human p53 gene: lack of association. Food Addit Contam 12:421-424 (1995). 46. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalig- nant human liver. Science 264:1317-1319 (1994). 47. Council on Scientific Affairs. Harmful effects of ultraviolet radiation. JAMA 262:380-384 (1989). 48. Stretch JR, Gatter KC, Ralfkiaer E, Lane DP, Harris AL. Expression of mutant p53 in melanoma. Cancer Res 51:5976-5979 (1991). 49. Reid TM, Loeb LA. Mutagenic specificity of oxygen radicals produced by human leukemia cells. Cancer Res 52:1082-1086 (1992). 50. Reid TM, Loeb LA. Tandem double CC-+TT mutations are produced by reactive oxygen species. Proc Natl Acad Sci USA 90:3904-3907 (1993). 51. Nakazawa H, English D, Randell P, Nakazawa K, Martel N, Armstrong BK, Yamasaki H. UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant expo- sure measurement. Proc Natl Acad Sci USA 91:360-364 (1994). 52. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutation in the p53 tumor suppressor gene: clues to cancer eti- ology and molecular pathogenesis. Cancer Res 54:4855-4878 (1994). 53. IARC. Tobacco Smoking. In: IARC Monographs on the Evaluation of Carcinogenic Risks. Vol 37. Lyon:International Agency for Research on Cancer, 1986. 54. Shopland DR, Eyre HJ, Pechacek TF. Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst 83:1142-1148 (1991). 55. Vineis P, Caporaso N. Tobacco and cancer: epidemiology and the laboratory. Environ Health Perspect 2:156-160 (1995). 56. Phillips DH, Hewer A, Martin CN, Garner RC, King MM. Correlation of DNA adduct levels in the human lung with cig- arette smoking. Nature 336:790-792 (1988). 57. Phillips DH, Schoket B, Hewer A, Bailey E, Kostic S, Vincze I. Influence of cigarette smoking on the levels of DNA adducts in human bronchial epithelium and white blood cells. Int J Cancer 46:569-576 (1990). 58. Geneste 0, Camus AM, Castegnaro M, Petruzzelli S, Macchiarini P, Angeletti CA, Giuntini C, Bartsch H. Comparison of pulmonary DNA-adduct levels, measured by 32P-post labelling and aryl hydrocarbon hydoxylase activity in lung parenchyma of smokers and ex-smokers. Carcinogenesis 12:1301-1305 (1991). 59. Alexandrov K, Rojas M, Geneste 0, Castegnaro M, Camus AM, Petruzzelli S, Guintini C, Bartsch H. An improved fluoro- metric assay for dosimetry of benzo(a)pyrene diol-epoxide- DNA adducts in smoker's lung: Comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res 53:6248-6251 (1993). 60. Vineis P. Epidemiological models for carcinogenesis: the exam- ple of bladder cancer. Cancer Epidemiol Biomarkers Prev 1:149-153 (1992). 61. Cherpillod P, Amstad PA. Benzo[a]pyrene-induced mutagene- sis of p53 hot-spot codons 248 and 249 in human hepatocytes. Mol Carcinog 13(1):15-20 (1995). 62. Chen B, Liu L, Castonguay A, Maronpot RR, Anderson MW, You M. Dose-dependent ras mutation spectra in N-nitrosodi- ethylamine induced mouse liver tumors and 4-(methylni- trosamino)-1-(3-pyridyl)-1-butanone induced mouse lung tumors. Carcinogenesis 14(8):1603-1608 (1993). 63. Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Ueda R. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res 52:734-736 (1992). 64. Wang X, Christiani DC, Wiencke JK Fischbein M, Xu C, Cheng TJ, Mark E, Wain JC, Kelsey KT. Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epidemiol Biomarkers Prev 4:543-548 (1995). 65. Takashima Y, Seyama T, Bennett WP, Akiyama M, Tokuoka S, Inai K, Mabuchi K, Land CE, Harris CC. p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet 342:8886-8887 (1993). 66. Lee LN, Shew JY, Sheu JC, Lee YC, Lee WC, Fnag MT, Chang HF, Yu CJ. Exon 8 mutation of p53 gene associated with nodal metastasis in non-small-cell lung cancer. Am J Respir Crit Care Med 150:1667-1671 (1994). 67. Morrison AS, Buring JE, Verhoek WG, Aoki K, Leck L, Ohno Y, Obata K. An international study of smoking and bladder cancer. J Urol 131:650-654 (1984). 68. Ross RK, Paganini-Hill A, Henderson BE. Epidemiology of bladder cancer. In: Diagnosis and Management of Genitourinary Cancer (Skinner DG, Lieskovsky G, eds). Philadelphia:WB Saunders Co, 1988; 23-31. 69. McLaughlin JK, Silverman DT, Hsing AW, Ross RK, Schoenberg JB, Yu MC, Stemhagen A, Lynch CF, Blot WJ, Fraumeni JF. Cigarette smoking and cancers of the renal pelvis and ureter. Cancer Res 52:254-257 (1992). 70. IARC. Schistosomes, Liver Flukes and Helicobacter Pylori. In: IARC Monographs on the Evaluation of Carcinogenic Risks. Vol 61. Lyon:International Agency for Research on Cancer, 1994;45-119. 71. Dosaka-Akita H, Shindoh M, Fujino M, Kinoshita I, Akie K, Katoh M, Kawakami Y. Abnormal p53 expression in human 162 Environmental Health Perspectives * Vol 105, Supplement 1 * February 1997 THE USE OF p53 AS A BIOMARKER lung cancer is associated with histologic subtypes and patient smoking history. Am J Clin Pathol 102:660-664 (1994). 72. Esteve A, Sorlie T, Martel-Planche G, Hollstein M, Kusters I, Lewalter J, Vineis P, Stephan-Odenthal M, Montesano R. Screening for p53 gene mutations in archived tumors of work- ers occupationally exposed to carcinogens: examples from analysis of bladder tumors. J Occup Environ Med 37:59-68 (1995). 73. Sidransky D, Von Eschenbach A, Tsai Y, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706-708 (1991). 74. Zhang ZF, Sarkis AS, Cordon-Cardo C, Dalbagni G, Melamed J, Aprikian A, Pollack D, Sheinfeld J, Herr HW, Fair WR. Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer. Cancer Epidemiol Biomarkers Prev 3:19-24 (1994). 75. Falk H, Creech JL, Heath CW, Johnson MN, Key MM. Hepatic disease among workers at a vinyl chloride polymeriza- tion plant. JAMA 230:59-64 (1974). 76. IARC. Vinyl Chloride, Polyvinylchloride and Vinyl Chloride and Vinyl Acetate Polymers. In: IARC Monographs on the Evaluation of Carcinogenic Risks. Vol 15. Lyon:International Agency for Research on Cancer, 1979;377-438. 77. Soini Y, Welsh JA, Ishak KG, Bennett WP. p53 mutation in primary hepatic angiosarcomas not associated with vinyl chlo- ride exposure. Carcinogenesis 16:2879-2881 (1995). 78. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747-752 (1969). 79. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassei, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250:1233-1238 (1990). 80. Ishioka C, Frebourg T, Yan YX, Vidal M, Friend SH, Schmidt S, Iggo R. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 5:124-129 (1993). 81. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYPlAl genes involved in human lung cancer. Carcinogenesis 14:1085-1089 (1993). 82. Wu WJ, Kakehi Y, Habuchi T, Kinoshita H, Ogawa 0, Terachi T, Huang CH, Chiang CP, Yoshida 0. Allelic fre- quency of p53 gene codon 72 polymorphism in urologic can- cers. Jpn J Cancer Res 86:730-736 (1995). 83. Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, Honn SE, Spitz MR. Higher lung cancer risk for young African- Americans with the Pro/Pro p53 genotype. Carcinogenesis 16:2205-2208 (1995). 84. Birgander R, Sjalander A, Rannug A, Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Beckman G, Beckman L. p53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 16:2233-2236 (1995). 85. Sjalander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L, Beckan G. p53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 16:1461-1464 (1995). 86. Runnebaum IB, Tong XW, Konig R, Hong Z, Korner K, Atkinson EN, Kreienberg R, Kieback DG. p53 -based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet 345:994 (1995). 87. Lancaster JM, Bronlee HA, Wiseman RW, Taylor J. p53 poly- morphism in ovarian and bladder cancer. Lancet 346:182 (1995). 88. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215-221 (1992). 89. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74:813-822 (1993). 90. Harvey M, McArthur MJ, Montgomery CA Jr, Butel JS,Bradley A, Donehower LA. Spontaneous and carcinogen- induced tumorigenesis in p53-deficient mice. Nat Genet 5:225-229 (1993) 91. Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery CA Jr, Park SH, Thompson T, Ford RJ, Bradley A. Effects of genetic background on tumorigenesis in p53- deficient mice. Mol Carcinog 14:16-22 (1995). 92. Harvey M, Vogel H, Morris D, Bernstein A, Donehower LA. A mutant p53 transgene accelerates tumor development in het- erozygous but not nullizygous p53-deficient mice. Nat Genet 9:305-311 (1995). 93. Lee JM, Abrahamson JL, Kandel R, Donehower LA, Bernstein A. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene 9:3731-3736 (1994). 94. Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet 8:66-69 (1994). 95. Nicol CJ, Harrison ML, Laposa RR, Gimelshtein IL, Wells PG. A teratologic suppressor role for p53 in benzo(a)pyrene- treated transgenic p53-deficient mice. Nat Genet 10: 181-187 (1995). 96. Stanley LA. Molecular aspects of chemical carcinogenesis: the roles of oncogenes and tumour suppressor genes. Toxicology 96:173-194 (1995). 97. Goldsworthy TL, Recio L, Brown K, Donehower LA, Mirsalis JC, Tennant RW, Purchase IFH Transgenic animals in toxicol- ogy. Fundam Appl Toxicol 22:8-19 (1994). 98. Hall PA, Lane DP. p53 in tumor pathology: can we trust immunohistochemistry? - revisited. J Pathol 172:1-4 (1994). 99. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52:6380-4 (1992). 100. Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, Hirsch A, Soussi T. Serum p53 antibodies as early markers of lung cancer. Nat Med 1:701-702 (1995). 101. Borresen AL, Eivind H, Smith-Sorensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ, Friend SH. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci USA 88:8405-8409 (1991). 102. Moyret C, Theillet C, Puig PL, Moles JP, Thomas G, Hamelin R. Relative efficiency of denaturing gradient gel electrophoresis and single strand conformation poiymorphism in the detection of mutations in exons 5 to 8 of the p53 gene. Oncogene 9:1739-1743 (1994). 103. Cerutti P, Hussain P, Purzand C, Aguilar F. Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene. Cancer Res 54:1934s-1938s (1994). 104. Chen PH, Lin SY, Wang CK, Chen YJ, Chen TC, Chang JG. "Hot spots" mutation analysis of p53 gene in gastrointestinal cancers by amplification of naturally occurring and artificially created restriction sites. Clin Chem 39:2186-2191 (1993). Environmental Health Perspectives * Vol 105, Supplement 1 * February 1997 163